Life Sciences Litigation Insights: April 2022
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share notable cases from 2021 and...
CRA has assisted clients in intellectual property (IP) matters concerning products and services in the life sciences sector, including Hatch-Waxman and BPCIA matters. We have also addressed patent, trademark, and copyright infringement, trade secret misappropriation, and IP licensing. Our experts have quantified damages based on lost profit and reasonable royalty methods and provided opinions on irreparable harm. In addition, we have experience addressing other forms of relief, such as rescission and disgorgement.
Our understanding of the unique dynamics of different therapeutic areas informs assessments of commercial success as a secondary indicator of non-obviousness and the claimed nexus between patented technologies and product success.
Engagements
- 01High-profile US patent litigation regarding HIV medicationsCRA was retained by plaintiffs ViiV Healthcare and other companies in their high-profile US patent litigation against Gilead Sciences, Inc., regarding HIV...View engagement
- 02Breach of contract damages analysis and testimonyCRA was retained by a leading national research university in a breach of contract dispute with a licensee of certain university patent rights related to a...View engagement
- 03CRA assess commercial success for rare disease drugCRA addressed issues relating to commercial success in patent litigation on behalf of an innovator company commercializing a drug for a rare disease. CRA...View engagement